



Universiteit  
Leiden

The Netherlands

## Does it still hurt? Perioperative opioid analgesia in different patient populations

Hoogd, S. de

### Citation

Hoogd, S. de. (2021, October 28). *Does it still hurt?: Perioperative opioid analgesia in different patient populations*. Retrieved from <https://hdl.handle.net/1887/3221331>

Version: Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/3221331>

**Note:** To cite this publication please use the final published version (if applicable).



# Chapter 9

---

## The influence of morbid obesity on the pharmacokinetics of morphine and morphine-3 and morphine-6-glucuronide

Sjoerd de Hoogd  
Pry Väitalo  
Albert Dahan  
Simone van Kralingen  
Michael M.W. Coughtrie  
Eric P.A van Dongen  
Bert van Ramshorst  
Catherijne A.J. Knibbe

*Clin Pharmacokinet.* 2017;56(12):1577-1587

## Abstract

### Introduction

Obesity is associated with many pathophysiological changes that may result in altered drug metabolism. The aim of this study is to investigate the influence of obesity on the pharmacokinetics of morphine, morphine-3-glucuronide (M3G), and morphine-6-glucuronide (M6G) through a combined analysis in morbidly obese patients and non-obese healthy volunteers.

### Methods

In this analysis, data from 20 morbidly obese patients (mean body mass index 49.9 kg/m<sup>2</sup> (range 37.6 to 78.6 kg/m<sup>2</sup>) and weight 151.3 kg (range 112 to 251.9 kg)) and 20 healthy volunteers (mean weight 70.6 kg (range 58 to 85 kg)) were included. Morbidly obese patients received 10 mg intravenous (I.V.) morphine after gastric bypass surgery, with additional morphine I.V. doses as needed. Healthy volunteers received an I.V. bolus morphine 0.1 mg/kg followed by an infusion of 0.030 mg/kg/h for 1 h. Population pharmacokinetic modelling was performed using NONMEM 7.2.

### Results

In morbidly obese patients, elimination clearance of M3G and M6G was decreased substantially compared to healthy volunteers ( $p < 0.001$ ). Regarding glucuronidation, only a slight decrease in formation of M6G and a delay in formation of M3G was found (both  $p < 0.001$ ). Obesity was also identified as a covariate for the peripheral volume of distribution of morphine ( $p < 0.001$ ).

### Conclusion

Metabolism of morphine is not altered in morbidly obese patients. However, decreased elimination of both M3G and M6G is evident, resulting in substantial increase in exposure to these two metabolites. A rational explanation of this finding is that it results from alterations in membrane transporter function and/or expression in the liver.

## Introduction

The prevalence of obesity (body mass index (BMI) > 30 kg/m<sup>2</sup>) and morbid obesity (BMI > 40 kg/m<sup>2</sup>) is increasing, with around 600 million obese people worldwide<sup>1</sup>. Obesity is associated with an increase in morbidity and mortality and numerous chronic diseases such as diabetes mellitus, cardiovascular diseases, and cancer.

There are several (patho)physiological changes associated with morbid obesity that may impact the pharmacokinetics of drugs. Obesity has been associated with changes in the expression and function of metabolic processes such as cytochrome P450 and conjugation enzymes, fatty liver infiltration, non-alcoholic steatohepatitis (NASH), and altered transporters<sup>2</sup>. These changes have been shown to impact metabolism of certain drugs, with for instance, increased glucuronidation of paracetamol in morbidly obese patients<sup>3</sup>, whereas the metabolism of midazolam is unaltered in morbidly obese patients undergoing bariatric surgery compared to non-obese control patients<sup>4</sup>, but was found to increase after gastric bypass-induced weight loss one year after surgery<sup>5</sup>. Data on liver blood flow, glomerular filtration and/or tubular-mediated mechanisms in morbidly obese patients are more inconclusive with, for example, data of unchanged cefazolin clearance in morbidly obese patients and unchanged or increased liver blood flow<sup>2,6</sup>.

Morphine is primarily metabolized by the liver uridine diphosphate glucuronosyltransferases (UGT) 2B7 to pharmacologically active metabolites morphine-3-glucuronide (M3G) and morphine-6-glucuronide (M6G). M3G has potential antagonistic or hyperalgesic properties<sup>7</sup>, while M6G appears to contribute to analgesia and sedation<sup>8</sup>. Despite the extensive use of morphine, data on the PK of morphine and glucuronide metabolites in morbidly obese patients are limited. A previous study reported an increased ratio between morphine metabolites and morphine after oral administration of morphine in gastric bypass patients when comparing their results to data in the literature<sup>9-11</sup>. In another study, intravenous morphine was administered to 14 healthy volunteers and the results compared to seven obese patients with biopsy-confirmed NASH. This study also suggested a higher area under the curve (AUC) of morphine glucuronides in NASH patients compared with healthy volunteers<sup>12</sup>.

In view of higher susceptibility for pain and the increased use of opioids in obese individuals<sup>13</sup>, and the fact that the adverse effects of opioids are feared in obese populations because of increased risk for respiratory depression, respiratory failure, and other opioid adverse effects<sup>14,15</sup>, knowledge on the pharmacokinetics of morphine and its metabolites in morbidly obese patients is necessary. This study investigates the pharmacokinetics of morphine and its pharmacologically

active glucuronides in morbidly obese patients using a population approach on the basis of a combined dataset of morbidly obese patients together with a historic cohort of healthy volunteers<sup>16,17</sup>

## Methods

### Patients

The data obtained in the morbidly obese patients were collected as part of a study in which the pharmacokinetics of multiple drugs was investigated<sup>18-20</sup>. Anaesthesia was standardized with induction of anaesthesia with propofol, atracurium and fentanyl, after which anaesthesia was maintained with continuous infusions of propofol and remifentanyl. For this original study, 20 morbidly obese patients (BMI > 40 kg/m<sup>2</sup>) were included who were scheduled to undergo laparoscopic gastric banding, gastric sleeve, or gastric bypass surgery (Table 1). Inclusion criteria were age between 18 and 60 years, BMI > 40 kg/m<sup>2</sup>, American Society of Anesthesiologists (ASA) physical status classification of II or III, and a normal renal and liver function as assessed by routine laboratory testing. Exclusion criteria were pregnancy, breastfeeding, and a known allergy to morphine. This study was approved by the local human research and ethics committee of the St. Antonius Ziekenhuis (VCMO, NL35861.100.11) and conducted in accordance with the principles of the Declaration of Helsinki and the Medical Research Involving Human Subjects Act (WMO) of The Netherlands. Before participation, all patients gave written informed consent.

For the control group, data were available from 20 healthy volunteers, 10 of each sex, who were enrolled as part of two other studies of which detailed information can be found in the references<sup>16,17</sup>. The subjects were healthy and did not have a history of illicit substance abuse. Approval was obtained from the Human Ethics Committee (Commissie Medisch Ethiek, Leids Universitair Medisch Centrum, Leiden, The Netherlands: protocol No. P00.034). Written and oral informed consent was given.

### Study design

In the prospective observational study (ClinicalTrials.gov:NCT01097148), 20 morbidly patients were studied on the day of gastric bypass surgery and afterwards. According to standard care, all patients received a bolus injection of 10 mg intravenous morphine at the end of the procedure for the prevention and/or treatment of postoperative pain. If needed based on the local postoperative pain protocol (Numerical Rating Scale  $\geq 4$ ), patients received additional intravenous boluses of morphine. Blood samples were drawn before induction of anaesthesia

( $t = 0$ ) and after 5, 15, 30, 45, 75, 90, 120, 150, 250, 420 min after first dose of intravenous morphine. Samples were immediately stored on ice, and within 1 h, samples were centrifuged for 10 min at 4°C temperature to obtain plasma samples and stored immediately at -80°C until analysis. The healthy volunteers received an intravenous morphine bolus 0.10 mg/kg dose followed by an infusion of 0.03 mg/kg/h for 1 h. Blood samples were collected at fixed times ( $t = 5, 10, 20, 30, 40, 50, 60, 65, 70, 80, 100, 130, 180, 300,$  and 420 min) after morphine bolus dose.

### Analysis

Samples from both studies were analysed in the same laboratory using a solid-phase extraction and reverse-phase high-performance liquid chromatography, which has been published previously<sup>16</sup>. The Lower Limit of Quantification (LLOQ) for the obese population was 1 µg/L for morphine, 2 µg/L for M3G, and 1 µg/L for M6G. For the analytic method of the healthy volunteer study, the LLOQ values for morphine and M3G were 2 and 30 µg/L. For M6G, the LLOQ values were 2, 5, and 6 µg/L.

### Population Pharmacokinetic Analysis and Internal Model Validation

Morphine and metabolite data of both datasets were analysed using non-linear mixed-effects modelling with NONMEM Version 7.2 software (Icon Development Solutions, Hanover, MD, USA)<sup>21</sup>, Pirana Version 2.9.1<sup>22</sup>, R Version 3.0.1<sup>23</sup>, Xpose Version 4.5.0<sup>22</sup> and Psn Version 3.6.2<sup>22</sup> software were used to evaluate and visualize the data. Identifiability of the model was verified using COMBOS (UCLA Biocybernetics Laboratory Los Angeles, CA, USA) software application (see Electronic Supplementary Material 1)<sup>24</sup>. Concentrations were expressed in nanomoles per litre, using the molecular weights of morphine, M3G and M6G (285.33 and 461.46 g/mol, respectively). The amount of administered morphine was corrected for morphine hydrochloride (molecular weight 321.8 g/mol). In the obese population, no data were below the LLOQ. In the healthy volunteer study, 5% ( $n = 16$  of 311) of the morphine concentrations, 4.5% ( $n = 14$  of 311) of the M3G concentrations, and 9.6% ( $n = 30$  of 311) of the M6G concentrations were below the LLOQ. The first below quantification observations were replaced with LLOQ/2 and the rest were discarded, according to the M6 method for handling data below the limit of quantification in population pharmacokinetic studies<sup>25</sup>.

Discrimination between different models was made by likelihood ratio test using the objective function value (OFV, i.e.,  $-2 \log$  likelihood  $[-2LL]$ ). A  $p$ -value of  $<0.05$ , representing a decrease of 3.84 in the OFV value between nested models with one degree of freedom, was considered statistically significant. In addition, goodness-of-fit plots for morphine, M3G and M6G (observed vs. individual-predicted concentrations,

observed vs. population-predicted concentrations, conditional weighted residuals (CWRES) vs. time, and CWRES vs. population-predicted concentrations plots) were used for diagnostic purposes. Residual variability was tested using proportional, additive, or combined proportional and additive error models. Furthermore, the confidence interval of the parameter estimates, the correlation matrix, and visual improvement of the individual plots were used to evaluate the model. The delay in formation of morphine metabolites was captured by testing a varying number of transit compartments. Mean transit time (MTT) was calculated from the transit compartment rate constant (Ktr) with  $n/Ktr$ , where  $n$  is the number of transit compartments.

The non-glucuronide clearance (direct unchanged urinary clearance and nonglucuronide metabolic clearance) was assumed to be 35% of total clearance of a 70-kg healthy subject, based on previous reports<sup>26</sup>. Total clearance ( $CL_{total}$ ) was calculated as M3G clearance ( $CL_{M3G}$ ) + M6G clearance ( $CL_{M6G}$ ) + non-glucuronide clearance ( $CL_{nonglucuronide}$ ). The volume of distribution of the two metabolites M3G and M6G was assumed to be equal ( $V_{M3G} = V_{M6G}$ ), owing to their comparable molecular structure and weight. Bootstrap procedure using 200 replicates was used to obtain non-parametric confidence intervals and to assess model robustness<sup>27</sup>. Predictability was evaluated with the normalised prediction distribution error method (2000 samples). Results of the normalised prediction distribution error are incorporated in Figure 2 as a replacement of CWRES vs. time and CWRES vs. population-predicted concentrations.

### Covariate analysis

Covariates were plotted independently against the individual estimates of pharmacokinetic parameters to visualize potential relations. Total Body Weight (TBW) was the main covariate of interest in this study. Age and sex were tested in preliminary models but were further explored in the final model. BMI was not tested because no individual height was available of the healthy volunteers.

Continuous covariates were tested using both power and linear equations:

$$P_i = P_p \times (1 + Y \times (COV - COV_{median})), \quad (1)$$

$$P_i = P_p \times (COV - COV_{median})^X, \quad (2)$$

In which  $P_i$  and  $P_p$  represent individual and population parameter estimates, COV represents the covariate,  $COV_{median}$  represents the median of the value of the covariate for the population,  $Y$  represents a correlation factor between the population parameter and the change in covariate value for a linear function, and  $X$  represents the exponential scaling factor for a power function. The categorical



covariate (sex) was examined by calculating a separate parameter for each category of the covariate.

Potential covariates were separately entered into the model and statistically tested by use of the likelihood ratio test. In addition, if applicable, it was evaluated whether the inter-individual variability ( $\eta$ ) in the parameter concerned decreased upon inclusion of the covariate on the parameter and whether the plot of the  $\eta$  vs. covariate was improved. Finally, using forward inclusion ( $p < 0.05$ , OFV decrease  $> 3.8$ ) and backward deletion ( $p < 0.001$ , OFV decrease 10.8), it was justified to include the covariate.

### Simulations

The final population pharmacokinetic model was used to simulate concentration-time curves. An intravenous bolus of 10 mg morphine HCL was simulated in four patients; two extremes of dataset (resp. 56 and 251.9 kg) and two patients in-between. Morphine as well as M3G and M6G concentrations were plotted vs. time.

### Statistical Analysis

Continuous data are presented as median (interquartile range (IQR)) and analysed using the Mann-Whitney test, or as mean  $\pm$  standard deviation and analysed using Student's *t* test, where appropriate.

## Results

### Patients

Twenty morbidly obese patients and 20 healthy volunteers were available for analysis. In total, in the obese group, 196 morphine, 196 M3G, and 196 M6G plasma samples were included for analysis. In the healthy volunteers, a total of 290 plasma samples of morphine, 289 plasma samples of M3G, and 285 plasma samples of M6G were included. Differences were the result of the samples below the LLOQ. A summary of patient characteristics is presented in Table 1. Morbidly obese patients received a higher morphine dose compared to the healthy volunteers ( $15.7 \pm 4.0$  mg vs.  $9.2 \pm 1.2$  mg,  $p < 0.05$ ).

**Table 1.** Summary of patients characteristics

	<b>Morbidly obese patients (n = 20)</b>	<b>Healthy volunteers (n = 20)</b>	<b>p-value</b>
Male/female	9/11	10/10	0.752
Age (years)	44.1 ± 10.6 (22 to 59)	25.5 ± 4.1 (20 to 36)	0.000
Body weight (kg)	150.5 ± 33.3 (112.0 to 251.9)	70.6 ± 8.82 (56.0 to 85.0)	<0.001
Body mass index (kg/m <sup>2</sup> )	49.9 ± 10.2 (37.9 to 78.6)		
Type of surgery (n,%)			
Gastric bypass	10 (50.0)	N/A	N/A
Gastric banding	7 (35.0)		
Gastric sleeve	3 (15.0)		
No. of samples per patient			<0.001
Morphine, median (IQR)	10 (10 to 10)	15 (14 to 15)	
M3G	10 (10 to 10)	15 (14 to 15)	
M6G	10 (10 to 10)	15 (13 to 15)	
Total amount of morphine (mg)	15.7 (4.0)	9.2 (1.2)	<0.001
Serum creatinine, median (IQR) (µmol/L)	63 (60 to 81)*	80 (-)	0.014

Values are expressed as mean ± standard deviation (range) unless specified otherwise. IQR,interquartile range; M3G, morphine-3-glucuronide; M6G, morphine-6-glucuronide, N/A = not applicable

\* = one value missing.


### Population Pharmacokinetic Model and Internal Model Evaluation

A three-compartment model for morphine, and a one-compartment model for M3G and M6G, with equalized volumes of distribution, best fitted the data (Figure 1). The introduction of multiple transit compartments in the formation of the glucuronides (for M3G n = 5, mean transit time = 3.05 min; for M6G n = 2, mean transit time = 12.7 min) improved the model significantly (p<0.001). Residual variability was best described by proportional error models, one for each compound, and calculated separately for each group. Table 2 shows the parameter estimates of the simple model without covariates.

In the covariate analysis, no substantial influence of TBW on the clearance of morphine was found. Significant influence of TBW was found on several other parameters, all in a non-linear manner. Elimination clearance of both metabolites decreased with TBW ( $CL_{E\ M3G}$  p<0.001, -16 OFV,  $CL_{E\ M6G}$  p<0.001, -92 OFV), and peripheral volume of morphine increased significantly with increasing TBW (p<0.001, -34 OFV). Formation clearance of M6G decreased with increasing TBW ( $CL_{F\ M6G}$  p<0.001, -26 OFV). Formation of M3G was delayed with increasing bodyweight

because the mean transit time was increased with TBW (Ktr ( $p < 0.001$ , -28 OFV). Imputing these functions resulted in reduction in interindividual variability ( $CL_{FM3G}$  24.3% to 20.8%,  $CL_{EM3G}$  89.0% to 65.9%,  $V_{M3G} = V_{M6G}$  32.3% to 29.7%, and Ktr2 37.7% to 36.8% (see Table 2).

Goodness-of-fit plots of the final covariate model are shown in Figure 2. The empirical Bayes estimates (EBEs) after adding the covariate functions are shown in Figure 3. This figure shows the population-predicted outcomes of the final covariate model and the influence of TBW on the parameters, where adding TBW improved the model significantly. Final model parameters are summarized in Table 2. The bootstrap analysis was successful in 98.5% of the runs and the obtained parameter confidence intervals were highly similar to the confidence intervals obtained from the standard errors (Table 2).



**Figure. 1** Schematic illustration of the population pharmacokinetic model of morphine and morphine glucuronides.

CLF formation clearance; CLE elimination clearance; Ktr, transit rate constant; M3G morphine-3-glucuronide; M6G morphine-6-glucuronide; Q, inter-compartmental clearance from the central compartment of morphine to the peripheral compartments of morphine; V1, central volume of distribution; V2<sub>M3G</sub>, V4<sub>M3G</sub>, peripheral compartments of morphine.


$$V_{M6G} = V_{M3G}, CL_{\text{non-glucuronide}} = 35\% \text{ of } CL_{\text{total}} (70 \text{ kg}), CL_{\text{total}} = CL_{\text{non-glucuronide}} + CL_{FM3G} + CL_{FM6G}$$

**Table 2.** Population pharmacokinetic parameters of the base and final pharmacokinetic model for morphine and glucuronides in healthy volunteers and morbidly obese patients and results of the bootstrap analysis


Parameter	Base model (RSE%)	Final model (RSE%)	Bootstrap (95% confidence interval)
<i>Morphine*</i>			
$CL_{FM3G}$ (L/min)	0.725 (4.0)	0.748 (3.0)	0.748 (0.706 to 0.797)
$CL_{FM6G}$ (L/min)	0.128 (6.0)	-	
$CL_{FM6G} = CL_{FM6G, 98.5 \text{ kg}} \cdot (TBW/98.5)^K$			
$CL_{FM6G, 98.5 \text{ kg}}$ (L)	-	0.129 (5.0)	0.130 (0.119 to 0.140)
K	-	-0.329 (36.0)	-0.310 (-0.534 to -0.125)
$V1_M$ (L)	3.96 (5.0)	4.62 (9.0)	4.66 (3.95 to 5.59)
$V4_M$ (L)	5.76 (18.0)	9.52 (33.0)	9.91 (6.10 to 15.7)
$V5_M$ (L)	101 (5.0)		
$V5_M = V_{98.5 \text{ kg}} \cdot (TBW/98.5)^L$			
$V_{98.5 \text{ kg}}$ (L)	-	118 (9.0)	117.5 (103.7 to 136.6)
L	-	0.483 (48.0)	0.453 (0.112 to 0.859)
Q2 (L/min)	0.625 (7.0)	0.814 (20.0)	0.834 (0.598 to 1.16)
Q3 (L/min)	1.27 (5.0)	1.29 (5.0)	1.28 (1.15 to 1.41)
Ktr (min <sup>-1</sup> )	1.58 (9.0)		
$Ktr = Ktr_{98.5 \text{ kg}} \cdot (TBW/98.5)^M$			
$Ktr_{98.5 \text{ kg}}$	-	1.68 (9.0)	1.71 (1.51 to 1.98)
M	-	-0.701 (30.0)	-0.71 (-0.106 to 0.375)
Ktr2 (min <sup>-1</sup> )	0.151 (5.0)	0.159 (7.0)	0.158 (0.146 to 0.172)
<i>Metabolites (M3G, M6G)</i>			
$V_{M3G} = V_{M6G}$ (L)	6.47 (7.0)	5.29 (13.0)	5.33 (4.28 to 6.52)
$CL_{EM3G}$ (L/min)	0.131 (14.0)	-	
$CL_{EM3G} = CL_{EM3G, 98.5 \text{ kg}} \cdot (TBW/98.5)^N$			
$CL_{EM3G, 98.5 \text{ kg}}$ (L)	-	0.134 (10.0)	0.134 (0.110 to 0.155)
N	-	-1.08 (22.0)	-1.06 (-1.53 to -0.60)
$CL_{EM6G}$ (L/min)	0.171 (15.0)	-	
$CL_{EM6G} = CL_{EM6G, 98.5 \text{ kg}} \cdot (TBW/98.5)^O$			
$CL_{EM6G, 98.5 \text{ kg}}$ (L)	-	0.149 (10.0)	0.154 (0.125 to 0.186)
O	-	-1.03 (31.0)	-1.06 (-1.64 to -0.56)
<i>Interindividual variability (%)</i>			
$CL_{FM3G}$	24.3 (12.0)	20.8 (10.0)	20.3 (16.8 to 23.4)
$CL_{EM3G}$	89.0 (19.0)	65.9 (20.0)	62.9 (41.9 to 86.1)
$V_{M3G} = V_{M6G}$	32.3 (12.0)	29.7 (12.0)	29.2 (22.6 to 35.8)
Ktr2	37.7 (13.0)	36.8 (13.0)	35.9 (27.1 to 43.6)
<i>Residual variability (%)</i>			
Healthy volunteers			
Proportional error for morphine	15.1 (16.0)	14.0 (7.0)	13.8 (12.0 to 15.7)
Proportional error for M3G	18.0 (25.0)	17.9 (12.0)	18.0 (14.3 to 21.5)
Proportional error for M6G	30.4 (19.0)	29.5 (8.0)	29.3 (24.2 to 32.8)

Parameter	Base model (RSE%)	Final model (RSE%)	Bootstrap (95% confidence interval)
Morbidly obese patients			
Proportional error for morphine	37.3 (22.0)	37.9 (11.0)	37.1 (29.2 to 44.7)
Proportional error for M3G	18.4 (17.0)	17.1 (8.0)	17.1 (14.9 to 19.1)
Proportional error for M6G	32.8 (37.0)	28.1 (9.0)	26.5 (21.5 to 30.7)
OFV (-2LL)	10311.38	10116.1	10038.1 (9774 to 10306)

\* formation clearances are reported as absolute values, with  $CL_{F,M3G}$  and  $CL_{F,M6G}$  being 65% of total morphine clearance (see also Figure 1).  $CL_{F}$ , formation clearance;  $CL_{E}$ , elimination clearance; KTR, transit rate constant; M3G, morphine-3-glucuronide; M6G, morphine-6-glucuronide; OFV, objective function variable; Q, inter-compartmental clearance from the central compartment of morphine to the peripheral compartments of morphine; RSE, relative standard error; TBW, total body weight; V, volume of distribution (See also Figure 1)



**Figure 2.** Goodness-of-fit plots of morbidly obese individuals ( $n = 20$ , blue rounds) and healthy volunteers ( $n = 20$ , red rounds). On the first row morphine (A), second row morphine-3-glucuronide (B), third row morphine-6-glucuronide (C). Please note scale differences in y-axis. NPDE; normalised prediction distribution error.




**Figure 3.** Post hoc parameters estimates of morbidly obese individuals ( $n = 20$ , filled squares) and healthy volunteers ( $n = 20$ , open rounds) from the final model *versus* total body weight, including morphine-3-glucuronide elimination clearance ( $CL_E$  M3G) *versus* total body weight (a), morphine-6-glucuronide elimination clearance ( $CL_E$  M6G) *versus* total body weight (b), morphine-3-glucuronide transit rate constant (Ktr) *versus* total body weight (c), morphine-6-glucuronide transit rate constant (Ktr2) *versus* total body weight (d), peripheral volume of distribution of morphine ( $V_{1M}$ ) *versus* total body weight (e), formation clearance of morphine-6-glucuronide ( $CL_F$  M6G) *versus* total body weight (f).

## Simulations

Figure 4 shows the model-predicted concentration-time profiles of morphine and its metabolites after an intravenous bolus dose of 10 mg of morphine and a 48-h continuous infusion of 2 mg  $hr^{-1}$  in four representative individuals from this study with a TBW of 56 kg, 75 kg, 125 kg and 253 kg. The figure shows that the pharmacokinetic profile of morphine (panels A,D) in this weight range is

comparable. However, more pronounced differences are shown in the morphine glucuronides. Here, when a bolus of morphine is given, the maximum concentration of M3G is higher in obese patients (panel B). In addition, as a result of decreased elimination clearance, the AUC is also increased in these patients. For M6G (panel C), an effect of TBW on formation clearance and elimination clearance results in lower peak concentrations, but an increased AUC in obese patients. After a continuous infusion of 48 h of infusion, the 253-kg patient has approximately a five times higher concentration of M3G and a three times higher concentration of M6G compared with the 56-kg healthy volunteer (panels D,E).



**Figure 4.** Population predicted morphine, morphine-3-glucuronide, morphine-6-glucuronide concentrations over time in four typical study patients (56, 75, 125 and 253 kg) after a 10 mg intravenous bolus dose of morphine hydrochloride (a,b,c) and a 2.0 mg/h continuous infusion of morphine hydrochloride for 48 hours (d,e,f).

## Discussion

As limited data are available on the pharmacokinetics of morphine in morbidly obese patients, this study aimed to evaluate the influence of obesity on the metabolism of intravenously administered morphine and its pharmacologically active glucuronides (M3G and M6G). The results of this study show that, besides a slight decrease in formation of M6G, the formation clearance of the main metabolite M3G is similar between the groups, although the formation was delayed. It has been reported before, that UGT-mediated drug metabolism is potentially increased in obese patients in comparison with non-obese patients<sup>28</sup>; for example, for paracetamol glucuronidation (and sulphation) is increased in obese patients<sup>3</sup>. The lack of influence of obesity on morphine glucuronidation in

the present study may be explained by the fact that morphine is a medium-to-high extraction ratio drug, assuming liver blood flow remains unchanged in morbidly obese patients<sup>2</sup>. Such drugs are rapidly metabolized depending on hepatic blood flow and are relatively insensitive to changes in enzyme activity<sup>14</sup>.

The most important finding of the current study is the decrease in elimination clearance of both morphine glucuronides, and the resulting increased exposure to these metabolites that may therefore be expected in the obese patients (Figure 4). Increased AUC ratios of glucuronides:morphine in obese patients when compared to the metabolic ratios reported for healthy adults in the literature has been reported before<sup>10</sup>. However, from a physiological perspective these results are somewhat unexpected because the elimination of morphine glucuronides in animals is mainly through renal excretion; i.e., only about 20% of the morphine glucuronides is excreted through bile<sup>29-31</sup>. Therefore, we did not expect such a dramatic reduction in glucuronide clearance in the obese patients, as the routine blood tests of renal function around surgery show no indication that our obese patients had an impaired renal function. A more likely explanation is that elimination of the morphine glucuronides in the bile plays a much larger role in special patient populations than previously thought, implying a significant role for hepatic transporters.

Multidrug resistance proteins MRP2 (ABCC2) and MRP3 (ABCC3) are known to be involved in the transport of morphine and metabolites. MRP2 is mainly involved in the efflux of molecules from hepatocytes to the bile, while MRP3 is involved in the efflux from hepatocytes to plasma<sup>32</sup>. A decrease in MRP2 activity could therefore lead to a decrease in morphine glucuronide elimination. It is also likely that obese individuals could have decreased MRP2 as a result of NASH. This condition is associated with alterations in the expression and function of metabolizing enzymes and transporters<sup>33,34</sup>. In a NASH model in the rat, impaired function of MRP2 resulted in significantly reduced biliary excretion of M3G<sup>32</sup>. Furthermore, there is genetic evidence in humans that the activity of MRP2 is critical for biliary excretion of substrates. In an inherited medical condition known as Dubin-Johnson syndrome, dysfunctional mutations in the *MRP2* gene cause impairment in biliary excretion of bilirubin, such as bilirubin glucuronides. Together with upregulation of MRP3, this results in jaundice in patients with Dubin-Johnson syndrome<sup>35</sup>.

A recent clinical study measured bile acids as a surrogate parameter for activity of protein expression of the hepatic basolateral efflux transporter Mrp-3<sup>12</sup>. Seven obese patients (mean BMI of 32 kg/m<sup>2</sup>) with confirmed NASH were included in a non-compartmental analysis and no differences in the pharmacokinetics of



morphine compared with healthy subjects were found. Healthy volunteers had no liver biopsy to confirm the absence of NASH. However, an increase of around 50% in the AUC of the glucuronides in the patients with NASH was reported<sup>12</sup>. Upregulated MRP3 could increase the efflux from the hepatocytes to plasma, thereby reducing the concentrations available to be excreted to bile by MRP2 and thus increasing the residence time of M3G in plasma. The question is whether a combination of upregulated MRP3 and a decreased functional MRP2 can account completely for the increased exposure to morphine glucuronides in obese patients. This study of Ferslew et al. shows that increasing severity of NASH correlates with increasing bile acids, meaning that increasing NASH severity may further increase MRP3-mediated efflux clearance<sup>12</sup>. Taking into consideration that our patients have a far greater BMI index (mean 49.9 kg/m<sup>2</sup>) compared to this study, the impact of the MRP2/MRP3 transporters is potentially even greater.

Remarkably, accumulation of the morphine glucuronides is also seen in other patient populations. The study of Ahlers et al. compared ICU patients (i.e. cardiac surgery patients and critically ill patients) with healthy volunteers and found that M3G elimination clearance was decreased independently of the creatinine levels<sup>36</sup>. Because these patients had a BMI of around 28 kg/m<sup>2</sup>, it is possible that obesity related factors may have caused these results. Moreover, another study found increased expression of MRP3 protein in post-mortem biopsy samples of critically ill ICU patients<sup>37</sup>. Similar results on accumulation of morphine glucuronides have been reported in children undergoing cardiac surgery compared with non-cardiac surgery children<sup>38</sup>. Whether induction or inactivation of transporters in the acute setting such as surgery can play a role in the metabolism of drugs is area for future research. For example, a rat model of acute sepsis showed upregulation of MRP3 mRNA levels<sup>39</sup>.

The time-concentration simulations in Figure 4 illustrate the large increase in exposure to M3G and M6G that may be expected in individuals of varying body weights. Although the structure of the metabolites is quite similar, the effect of TBW on their profiles is different. This is the result of the different covariate functions on the M6G compared to M3G, and possibly of the lower fraction of morphine that is converted to M6G and the different UGT enzymes responsible for glucuronidation of the metabolites<sup>8</sup>. The clinical relevance of increased concentrations of M3G and M6G is however not clear. The general assumption is that M3G, although showing higher plasma concentrations, has lower opioid receptor binding affinity compared to morphine and lacks opioid activity, although some studies have reported anti-analgesic effects<sup>40-42</sup>. However, M6G binds with high affinity to the opioid receptor and contributes to the analgesic properties of

morphine<sup>8</sup>. There is a slow equilibration of the glucuronides between plasma and effect sites in the central nervous system, which is why the contribution of the glucuronides can become more important in prolonged exposure or decreased clearance for example in renal failure<sup>43</sup>. Recently it has become clear that morbidly obese patients 6 months after gastric bypass surgery had an increase in morphine exposure after oral administration<sup>9</sup>. The exposure of morphine increased probably because of an increase in absorption, while the exposure of glucuronides remained the same compared to pre-surgery state. This suggests a pathophysiological change after weight loss such as decrease in glucuronidation capacity, an increase in elimination clearance, or altered liver blood flow and/or liver membrane transporters.

There were some limitations in this study. First, even though the impact is expected to be small since morphine is administered at the end of surgery, the effects of anaesthesia and surgery on the pharmacokinetics of morphine and its metabolites cannot be assessed. Second, morbidly obese patients were not screened for the presence of NASH because no liver biopsy was taken. Third, TBW was the only body size descriptor available to investigate in this study. Last, no urinary samples were available to measure the concentrations of morphine and its metabolites. In this study, the measurements of morphine, M3G and M6G concentrations came from the same blood samples. The measurements can therefore be assumed to be correlated. While it would have been technically possible to estimate the intra-sample correlations between the concentrations, this was not considered relevant for the estimation of the pharmacokinetic parameters, their variances, and their covariates.

Future studies evaluating the influence of hepatic transporters and bile acid homeostasis in morbidly obese patients and after bariatric surgery are needed to understand more of the pathophysiological changes associated with obesity. In addition, studies should evaluate the clinical effects of increased morphine glucuronides in terms of efficacy and safety.

## Conclusion

In morbidly obese patients, the pharmacokinetics of morphine are comparable to healthy volunteers, thus no weight-based dosing adjustments are necessary for pharmacokinetic purposes. However, the elimination clearance of both M3G and M6G are significantly decreased resulting in increased exposure to the metabolites, especially with prolonged administration of morphine. A suggested underlying mechanism is a change in membrane transporters that are associated with

patients with NASH, a hepatic condition common in obese individuals. Additional mechanisms of increased glucuronide concentrations is area for future research, together with the pharmacodynamic and clinical consequences of increased M3G and M6G concentrations, especially.

## **Acknowledgements**

Sabine Ahlers is acknowledged for her contributions to this work. Part of this work was carried out on the Dutch national e-infrastructure with the support of SURF Foundation.

## Literature

1. (WHO), W. H. O. Factsheet obesity and overweight. 2016,
2. Knibbe, C. A. *et al.* Drug disposition in obesity: toward evidence-based dosing. *Annu. Rev. Pharmacol. Toxicol.* 55, 149–167 (2015).
3. van Rongen, A. *et al.* Morbidly Obese Patients Exhibit Increased CYP2E1-Mediated Oxidation of Acetaminophen. *Clin. Pharmacokinet.* 55, 833–847 (2016).
4. Brill, M. J. *et al.* Midazolam pharmacokinetics in morbidly obese patients following semi-simultaneous oral and intravenous administration: a comparison with healthy volunteers. *Clin. Pharmacokinet.* 53, 931–941 (2014).
5. Brill, M. J. *et al.* The Pharmacokinetics of the CYP3A Substrate Midazolam in Morbidly Obese Patients Before and One Year After Bariatric Surgery. *Pharm. Res.* 32, 3927–3936 (2015).
6. Brill, M. J. *et al.* Reduced subcutaneous tissue distribution of cefazolin in morbidly obese versus non-obese patients determined using clinical microdialysis. *J. Antimicrob. Chemother.* 69, 715–723 (2014).
7. Martini, C., Olofsen, E., Yassen, A., Aarts, L. & Dahan, A. Pharmacokinetic-pharmacodynamic modeling in acute and chronic pain: an overview of the recent literature. *Expert Rev. Clin. Pharmacol.* 4, 719–728 (2011).
8. Sverrisdottir, E. *et al.* A review of morphine and morphine-6-glucuronide's pharmacokinetic-pharmacodynamic relationships in experimental and clinical pain. *Eur. J. Pharm. Sci.* 74, 45–62 (2015).
9. Lloret-Linares, C., Scherrmann, J.-M. & Declèves, X. The effect of morbid obesity on morphine glucuronidation. *Pharmacol. Res.* 114, 299–300 (2016).
10. Lloret-Linares, C. *et al.* Oral Morphine Pharmacokinetic in Obesity: The Role of P-Glycoprotein, MRP2, MRP3, UGT2B7, and CYP3A4 Jejunal Contents and Obesity-Associated Biomarkers. *Mol. Pharm.* 13, 766–773 (2016).
11. Lloret-Linares, C. *et al.* Effect of a Roux-en-Y gastric bypass on the pharmacokinetics of oral morphine using a population approach. *Clin. Pharmacokinet.* 53, 919–930 (2014).
12. Ferslew, B. C. *et al.* Altered morphine glucuronide and bile acid disposition in patients with nonalcoholic steatohepatitis. *Clin. Pharmacol. Ther.* 97, 419–427 (2015).
13. Hitt, H. C., McMillen, R. C., Thornton-Neaves, T., Koch, K. & Cosby, A. G. Comorbidity of obesity and pain in a general population: results from the Southern Pain Prevalence Study. *J. Pain* 8, 430–436 (2007).
14. Lloret Linares, C. *et al.* Pharmacology of morphine in obese patients: clinical implications. *Clin. Pharmacokinet.* 48, 635–51 (2009).
15. Rose, D. K., Cohen, M. M., Wigglesworth, D. F. & DeBoer, D. P. Critical respiratory events in the postanesthesia care unit. Patient, surgical, and anesthetic factors. *Anesthesiology* 81, 410–418 (1994).
16. Sarton, E. *et al.* Sex differences in morphine analgesia: an experimental study in healthy volunteers. *Anesthesiology* 93, 1245–54; discussion 6A (2000).
17. Romberg, R. *et al.* Pharmacokinetic-pharmacodynamic modeling of morphine-6-glucuronide-induced analgesia in healthy volunteers: absence of sex differences. *Anesthesiology* 100, 120–133 (2004).
18. van Kralingen, S. *et al.* Pharmacokinetics and protein binding of cefazolin in morbidly obese patients. *Eur. J. Clin. Pharmacol.* 67, 985–92 (2011).

19. van Kralingen, S. *et al.* Comparative evaluation of atracurium dosed on ideal body weight vs. total body weight in morbidly obese patients. *Br. J. Clin. Pharmacol.* 71, 34–40 (2011).
20. Diepstraten, J. *et al.* Population pharmacodynamic model for low molecular weight heparin nadroparin in morbidly obese and non-obese patients using anti-Xa levels as endpoint. *Eur. J. Clin. Pharmacol.* 71, 25–34 (2015).
21. Beal, S., Sheiner, L. B., Boeckmann, A. & Bauer, R. J. *NONMEM user's guide (1989-2009)*. (Ellicott City: Icon Development Solutions, 2009).
22. Keizer, R. J., Karlsson, M. O. & Hooker, A. Modeling and Simulation Workbench for NONMEM: Tutorial on Pirana, PsN, and Xpose. *CPT pharmacometrics Syst. Pharmacol.* 2, e50 (2013).
23. Team., R. D. C. R: a language and environment for statistical computing. Vienna: R Foundation for Statistical Computing. *Vienna R Found. Stat. Comput.* (2008).
24. Meshkat, N., Kuo, C. E. & DiStefano 3rd, J. On finding and using identifiable parameter combinations in nonlinear dynamic systems biology models and COMBOS: a novel web implementation. *PLoS One* 9, e110261 (2014).
25. Beal, S. L. Ways to fit a PK model with some data below the quantification limit. *J. Pharmacokinet. Pharmacodyn.* 28, 481–504 (2001).
26. Andersen, G., Christrup, L. & Sjogren, P. Relationships among morphine metabolism, pain and side effects during long-term treatment: an update. *J. Pain Symptom Manage.* 25, 74–91 (2003).
27. Yafune, A. & Ishiguro, M. Bootstrap approach for constructing confidence intervals for population pharmacokinetic parameters. I: A use of bootstrap standard error. *Stat. Med.* 18, 581–599 (1999).
28. Brill, M. J. *et al.* Impact of obesity on drug metabolism and elimination in adults and children. *Clin. Pharmacokinet.* 51, 277–304 (2012).
29. Christrup, L. L. Morphine metabolites. *Acta Anaesthesiol. Scand.* 41, 116–122 (1997).
30. Ouellet, D. M. & Pollack, G. M. Biliary excretion and enterohepatic recirculation of morphine-3-glucuronide in rats. *Drug Metab. Dispos.* 23, 478–484 (1995).
31. Garrett, E. R. & Jackson, A. J. Pharmacokinetics of morphine and its surrogates. III: Morphine and morphine 3-monoglucuronide pharmacokinetics in the dog as a function of dose. *J. Pharm. Sci.* 68, 753–771 (1979).
32. Dzierlenga, A. L. *et al.* Mechanistic basis of altered morphine disposition in nonalcoholic steatohepatitis. *J. Pharmacol. Exp. Ther.* 352, 462–470 (2015).
33. Fisher, C. D. *et al.* Hepatic cytochrome P450 enzyme alterations in humans with progressive stages of nonalcoholic fatty liver disease. *Drug Metab. Dispos.* 37, 2087–2094 (2009).
34. Hardwick, R. N. *et al.* Altered UDP-glucuronosyltransferase and sulfotransferase expression and function during progressive stages of human nonalcoholic fatty liver disease. *Drug Metab. Dispos.* 41, 554–561 (2013).
35. Konig, J., Rost, D., Cui, Y. & Keppler, D. Characterization of the human multidrug resistance protein isoform MRP3 localized to the basolateral hepatocyte membrane. *Hepatology* 29, 1156–1163 (1999).
36. Ahlers, S. J. *et al.* Morphine Glucuronidation and Elimination in Intensive Care Patients: A Comparison with Healthy Volunteers. *Anesth. Analg.* 121, 1261–1273 (2015).

37. Vanwijngaerden, Y. M. *et al.* Critical illness evokes elevated circulating bile acids related to altered hepatic transporter and nuclear receptor expression. *Hepatology* 54, 1741–1752 (2011).
38. Valkenburg, A. J. *et al.* Pharmacodynamics and Pharmacokinetics of Morphine After Cardiac Surgery in Children With and Without Down Syndrome. *Pediatr. Crit. Care Med.* 17, 930–938 (2016).
39. Cherrington, N. J., Slitt, A. L., Li, N. & Klaassen, C. D. Lipopolysaccharide-mediated regulation of hepatic transporter mRNA levels in rats. *Drug Metab. Dispos.* 32, 734–741 (2004).
40. Smith, M. T., Watt, J. A. & Cramond, T. Morphine-3-glucuronide--a potent antagonist of morphine analgesia. *Life Sci.* 47, 579–585 (1990).
41. Gong, Q. L., Hedner, T., Hedner, J., Bjorkman, R. & Nordberg, G. Antinociceptive and ventilatory effects of the morphine metabolites: morphine-6-glucuronide and morphine-3-glucuronide. *Eur. J. Pharmacol.* 193, 47–56 (1991).
42. Mercadante, S. The role of morphine glucuronides in cancer pain. *Palliat. Med.* 13, 95–104 (1999).
43. Dahan, A. & Lotsch, J. Morphine is not a prodrug. *Br. J. Anaesth.* 114, 1005–1006 (2015).

## Supplemental Material

**Output COMBOS: <http://biocyb1.cs.ucla.edu/combos/>**

### **Only Positive Solutions**

CLf3 is uniquely identifiable

CLf6 is uniquely identifiable

Q1 is locally identifiable with 2 solutions

Q2 is locally identifiable with 2 solutions

V1 is uniquely identifiable

V2 is locally identifiable with 2 solutions

V3 is locally identifiable with 2 solutions

CLe3 is uniquely identifiable

V4 is uniquely identifiable

CLe6 is uniquely identifiable

*COMBOS Runtime = 25.00 seconds*

**Supplemental file - NONMEM model code of final model**

```

$SUBROUTINE ADVAN6 TOL9
$MODEL
COMP (CENTRAL,DEFDOSE)
COMP (COMP1) ;M3G
COMP (COMP2) ;M6G
COMP (PERIPH1) ; Peripheral cmt for parent
COMP (PERIPH2) ; Peripheral cmt for parent
COMP (BUFFER) ;m6g
COMP (BUFFER2) ;m6g
COMP (BUFFER3) ;m3g
COMP (BUFFER4) ;m3g
COMP (BUFFER5) ;m3g
COMP (BUFFER6) ;m3g
COMP (BUFFER7) ;m3g

```

```

$PK
TVCL1=THETA(1)
CL1=TVCL1*EXP(ETA(1))
TVV1=THETA(2)
V1=TVV1*EXP(ETA(2))
TVCL2=THETA(3)*(WT/98.5)**THETA(14)
CL2=TVCL2*EXP(ETA(3))
TVCL3=THETA(4)*(WT/98.5)**THETA(15)
CL3=TVCL3*EXP(ETA(4))
TVCL4=THETA(5)*(WT/98.5)**THETA(12)
CL4=TVCL4*EXP(ETA(5))
TVQ2=THETA(6)
Q2=TVQ2*EXP(ETA(6))
TVQ3=THETA(7)
Q3=TVQ3*EXP(ETA(7))
TVV5=THETA(8)*(WT/98.5)**THETA(13)
V5=TVV5*EXP(ETA(8))
TVV2=V1*THETA(9)
V2=TVV2*EXP(ETA(9))
V3=V2
TVV4=THETA(11)
V4=TVV4*EXP(ETA(11))

```



TVKTR=THETA(10)  
 KTR=TVKTR\*EXP(ETA(10))  
 TVKTR2=THETA(16)\*(WT/98.5)\*\*THETA(17)  
 KTR2=TVKTR2\*EXP(ETA(12))  
 K18=CL1/V1  
 K16=CL2/V1  
 K10=0.35\*((CL1 + THETA(3)\*(70/98.5)\*\*THETA(14))/0.65)/V1 ;CL0/V1  
 K67=KTR  
 K73=KTR  
 K89=KTR2  
 K910=KTR2  
 K1011=KTR2  
 K1112=KTR2  
 K122=KTR2  
 K20=CL3/V2  
 K30=CL4/V3  
 K14=Q2/V1  
 K41=Q2/V4  
 K15=Q3/V1  
 K51=Q3/V5  
 S1=V1  
 S2=V2  
 S3=V3  
 S4=V4  
  
 ET1=ETA(1)  
 ET2=ETA(2)  
 ET3=ETA(3)  
 ET4=ETA(4)  
 ET5=ETA(5)  
 ET6=ETA(6)  
 ET7=ETA(7)  
 ET8=ETA(8)  
 ET9=ETA(9)  
 ET10=ETA(10)  
 ET11=ETA(11)

## \$DES

$$\text{DADT}(1) = -(K18 + K16 + K10 + K14 + K15) * A(1) + K41 * A(4) + K51 * A(5)$$

$$\text{DADT}(2) = K122 * A(12) - K20 * A(2)$$

$$\text{DADT}(3) = K73 * A(7) - K30 * A(3)$$

$$\text{DADT}(4) = K14 * A(1) - K41 * A(4)$$

$$\text{DADT}(5) = K15 * A(1) - K51 * A(5)$$

$$\text{DADT}(6) = K16 * A(1) - K67 * A(6)$$

$$\text{DADT}(7) = K67 * A(6) - K73 * A(7)$$

$$\text{DADT}(8) = K18 * A(1) - K89 * A(8)$$

$$\text{DADT}(9) = K89 * A(8) - K910 * A(9)$$

$$\text{DADT}(10) = K910 * A(9) - K1011 * A(10)$$

$$\text{DADT}(11) = K1011 * A(10) - K1112 * A(11)$$

$$\text{DADT}(12) = K1112 * A(11) - K122 * A(12)$$

## \$ERROR

$$\text{COM1} = 0$$

$$\text{IF (CMT.EQ.1) COM1} = 1$$

$$\text{COM2} = 0$$

$$\text{IF (CMT.EQ.2) COM2} = 1$$

$$\text{COM3} = 0$$

$$\text{IF (CMT.EQ.3) COM3} = 1$$

$$Y1 = F * (1 + \text{ERR}(1)) * (1 - \text{OBES}) + \text{ERR}(4) * \text{OBES}$$

$$Y2 = F * (1 + \text{ERR}(2)) * (1 - \text{OBES}) + \text{ERR}(5) * \text{OBES}$$

$$Y3 = F * (1 + \text{ERR}(3)) * (1 - \text{OBES}) + \text{ERR}(6) * \text{OBES}$$

$$Y = \text{COM1} * Y1 + \text{COM2} * Y2 + \text{COM3} * Y3$$

$$\text{IPRED} = F$$

$$\text{IRES} = \text{DV} - \text{IPRED}$$

$$\text{DEL} = 0$$

$$\text{IF (IPRED.EQ.0) DEL} = 1$$

$$\text{IWRES} = (1 - \text{DEL}) * \text{IRES} / (\text{IPRED} + \text{DEL})$$

## \$THETA

$$(0, 0.8) ; \text{CL1}$$

$$(0, 5) ; \text{V1}$$

$$(0, 0.15) ; \text{CL2}$$

$$(0, 0.15) ; \text{CL3}$$

$$(0, 0.15) ; \text{CL4}$$

$$(0, 0.9) ; \text{Q2}$$

$$(0, 1.27) ; \text{Q3}$$

(0, 110) ; V5  
 (0, 5,1000) ; V2  
 (0, 0.158) ; KTr  
 (0, 8) ; V4  
 (-2, -1.02,20) ; \*CL4  
 (-0.9, 0.468,20) ; \*V5  
 (-2, -0.272,20) ; \*CL2  
 (-2, -1.08,20) ; \*CL3  
 (0, 1.64,1000) ; ktr2 (m3g)  
 (-2,-0.5,20) ; \*KTR2

## \$OMEGA

0.08 ; CL1  
 0 FIX ; V1  
 0 FIX ; CL2  
 0.4 ; CL3  
 0 FIX ; CL4  
 0 FIX ; Q2  
 0 FIX ; Q3  
 0 FIX ; V5  
 0.0889 ; V2=V3  
 0.3 ; KTR  
 0 FIX ; V4  
 0 FIX ; KTR2  
 0 FIX ;

## \$SIGMA

0.01; SIGMA1 parent  
 0.05  
 0.05  
 \$SIGMA  
 0.1 ; SIGMA1 parent, obese  
 0.05  
 0.05